Mo = month; No.= Number of; OCS= oral corticosteroids; IgE=
Immunoglobulin E.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)) or as median with
interquartile ranges (median [IQR25;
IQR75]; Comparisons between groups were performed
using Kruskal-Wallis tests with Dunn’s post-tests for quantitative
variables and Chi-square tests for categorical variables. Statistical
significance (bold): p<0.05 (a
p<0.05 for No-Ex vs Low-Ex; b
p<0.05 for No-Ex vs High-Ex; c
p<0.05 for Low-Ex vs High-Ex).
|
Mo = month; No.= Number of; OCS= oral corticosteroids; IgE=
Immunoglobulin E.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)) or as median with
interquartile ranges (median [IQR25;
IQR75]; Comparisons between groups were performed
using Kruskal-Wallis tests with Dunn’s post-tests for quantitative
variables and Chi-square tests for categorical variables. Statistical
significance (bold): p<0.05 (a
p<0.05 for No-Ex vs Low-Ex; b
p<0.05 for No-Ex vs High-Ex; c
p<0.05 for Low-Ex vs High-Ex).
|
Mo = month; No.= Number of; OCS= oral corticosteroids; IgE=
Immunoglobulin E.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)) or as median with
interquartile ranges (median [IQR25;
IQR75]; Comparisons between groups were performed
using Kruskal-Wallis tests with Dunn’s post-tests for quantitative
variables and Chi-square tests for categorical variables. Statistical
significance (bold): p<0.05 (a
p<0.05 for No-Ex vs Low-Ex; b
p<0.05 for No-Ex vs High-Ex; c
p<0.05 for Low-Ex vs High-Ex).
|
Mo = month; No.= Number of; OCS= oral corticosteroids; IgE=
Immunoglobulin E.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)) or as median with
interquartile ranges (median [IQR25;
IQR75]; Comparisons between groups were performed
using Kruskal-Wallis tests with Dunn’s post-tests for quantitative
variables and Chi-square tests for categorical variables. Statistical
significance (bold): p<0.05 (a
p<0.05 for No-Ex vs Low-Ex; b
p<0.05 for No-Ex vs High-Ex; c
p<0.05 for Low-Ex vs High-Ex).
|
Mo = month; No.= Number of; OCS= oral corticosteroids; IgE=
Immunoglobulin E.
Patients were divided according to their number of exacerbations in the
year following bronchoscopy in No-Ex (0 exacerbation), Low-Ex (1-2
exacerbations) and High-Ex (≥3 exacerbations). Results are presented as
absolute values and percentage (n/N (%)) or as median with
interquartile ranges (median [IQR25;
IQR75]; Comparisons between groups were performed
using Kruskal-Wallis tests with Dunn’s post-tests for quantitative
variables and Chi-square tests for categorical variables. Statistical
significance (bold): p<0.05 (a
p<0.05 for No-Ex vs Low-Ex; b
p<0.05 for No-Ex vs High-Ex; c
p<0.05 for Low-Ex vs High-Ex).
|